Limited evidence for biological treatment measures for cartilage and tendon injuries of the shoulder

Abstract Purpose To critically review the available literature on the usage of biologics to treat cartilage and tendon injuries of the shoulder. Methods Four different databases were searched in January 2020 for studies reporting data on bone marrow stimulation, autologous chondrocyte implantation, platelet‐rich plasma, autologous concentrated serum, and bone marrow aspirate concentrate for the treatment of cartilage and/or tendon injuries of the shoulder. Prospective, retrospective, cohort and case–control studies as well as case series, systematic reviews and laboratory studies (involving human tissue) were included. Cadaveric or animal studies were excluded. Findings were summarized and an expert opinion on trends was provided. Results Although there is limited literature available on biologics in cartilage lesions of the shoulder, the advancement from micro‐ to nanofracture, that is well established for the treatment of cartilage lesions in the knee, may be the next step in the treatment of shoulder lesions as well. The high rate of failure and therefore the complexity of tendon healing following rotator cuff repair has led to a rising interest in biologic augmentation such as platelet‐rich plasma and stem cells to enhance tendon‐bone‐healing and to decrease the prevalence of failure. Despite the increase in publications, there exists a huge heterogeneity of content, quality, and quantity of among studies and their processing methods reporting the use of platelet‐rich plasma in rotator cuff repair. Conclusion Conclusions from individual studies cannot be generalized. Currently, no evidence supports that platelet‐rich plasma provides clinical benefits in rotator cuff repair. Similar is reported for microfracture in rotator cuff repair, however, despite no clinical benefits, microfracture has shown to reduce the appearance of structural failures. Although some evidence exists for the use of stem cells form bone marrow aspirate concentrate, results from large case series are still lacking. Level of evidence Level V.